FDA approves first plasmid DNA-based immunotherapy for adults with recurrent respiratory papillomatosis
INO•The FDA granted accelerated approval to Inovio Pharmaceuticals’ Voceryq for adults with recurrent respiratory papillomatosis, making it the first plasmid DNA-based immunotherapy approved for the condition.
1. FDA approval
The FDA granted accelerated approval to Inovio Pharmaceuticals’ Voceryq for adults with recurrent respiratory papillomatosis. The therapy is the first plasmid DNA-based immunotherapy approved for the condition.
